Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.87 -0.38 (-2.34%)
Official Closing Price Updated: 7:00 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
News headline image
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
News headline image
Takeda In-Licenses Hunter Syndrome Candidate ↗
Takeda Pharmaceutical Company Limited (NYSE: TAK) and JCR Pharmaceuticals Co Ltd have announced an exclusive collaboration and license agreement to... 
Via Benzinga
News headline image
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug ↗
In a spat between Takeda Pharmaceutical Co Ltd (NYSE: TAK) and AbbVie Inc (NYSE: ABBV) for Lupron (leuprorelin), a Delaware judge has issued a ruling in... 
Via Benzinga
News headline image
Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
9 Health Care Stocks Showing Unusual Options Activity In Today's Session ↗
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
News headline image
Mirum, Takeda Ink Maralixibat Licensing Pact In Japan ↗
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for... 
Via Benzinga
News headline image
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight ↗
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
News headline image
Takeda's Exkivity Scores FDA Nod As First Oral Therapy For Lung Cancer With EGFR Exon20 Insertion ↗
The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Exkivity (mobocertinib) for non-small cell lung cancer (NSCLC) settings. The approval comes for... 
Via Benzinga
News headline image
Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Pressure Day ↗
Today a recovery came to markets with a particular impact on uranium shares. 
Via Talk Markets
News headline image
ADHD Drug Developer Cingulate Plans NASDAQ Debut ↗
Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention... 
Via Benzinga
Topics Initial Public Offering
News headline image
Why Novavax Stock Is Slipping Again Today ↗
A reported delay in India's EUA for Novavax's COVID-19 vaccine appears to still be weighing on the stock. 
Via The Motley Fool
News headline image
Why Novavax Stock Surged Today ↗
The biotech's coronavirus-related revenue could be about to soar. 
Via The Motley Fool
News headline image
NVAX Stock: The Big Reason Why Novavax Shares Are Gaining Today ↗
A Japanese pharma giant has partnered with Novavax to supply millions of vaccines. NVAX stock is reacting accordingly. 
Via InvestorPlace
News headline image
Novavax Shares Surge On Vaccine Supply Deal With Japan ↗
Novavax, Inc. shares were trading higher Tuesday following the signing of a coronavirus vaccine supply deal. 
Via Talk Markets
News headline image
Novavax Shares Surge On Vaccine Supply Deal With Japan ↗
Novavax, Inc. (NASDAQ: NVAX) shares were trading higher Tuesday following the signing of a coronavirus vaccine supply deal. What Happened: Japanese pharma giant Takeda... 
Via Benzinga
News headline image
Mu - The Newest Worry ↗
Today London and New York fell on the huge drop in new employment levels in August. 
Via Talk Markets
News headline image
Takeda's Breakthrough Blood Cancer Drug Flunks In Phase 3 Study ↗
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced topline data from the Phase 3 PANTHER study evaluating pevonedistat in blood cancer indications. The trial did... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV... 
Via Benzinga
News headline image
Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Moderna Reviews Contamination In Vaccine Lot Distributed In Japan ↗
Moderna, Inc. (NASDAQ: MRNA) found itself in a controversy after Japan suspended the use of about 2.6 million doses of the company's COVID-19 vaccine following reports of... 
Via Benzinga
News headline image
UK's NICE Rejects Johnson & Johnson's Darzalex Regime For Newly Diagnosed Myeloma ↗
New guidance from the National Institute for Health and Care Excellence (NICE) has rejected a combination regimen based on Johnson & Johnson's (NYSE: JNJ)... 
Via Benzinga
News headline image
Moderna Withdraws Additional COVID-19 Shots In Japan: What You Need To Know ↗
After receiving reports on more contaminated vials and two deaths, Japan has suspended another million doses of Moderna Inc's (NASDAQ: MRNA) COVID-19... 
Via Benzinga
Topics Death
News headline image
Suspected Metallic Particles Behind Moderna's Japan COVID-19 Jab Contamination: Reuters ↗
Metallic particle is believed to be a contaminant found in a batch of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccines delivered to Japan, Japanese public broadcaster... 
Via Benzinga
News headline image
Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer ↗
Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received... 
Via Benzinga
News headline image
Moderna Withdraws 1.6M COVID-19 Vaccine Doses In Japan Over Contamination Concerns ↗
More than a million doses of Moderna Inc’s (NASDAQ: MRNA) coronavirus vaccine have been taken out of circulation in Japan after reports of contamination emerged, Nikkei Asia... 
Via Benzinga
News headline image
BioLife Plasma Services Opens First All-Electric Plasma Donation Center
From Takeda Pharmaceutical Company Limited
Via Business Wire
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.